1. The Cholinergic System as a Treatment Target for Opioid Use Disorder

   • Kevin P. Jensen
   • Elise E. DeVito
   • Mehmet Sofuoglu

   Leading Article 26 September 2018 Pages: 981 - 996

2. Ketamine for Refractory Status Epilepticus: A Systematic Review

   • Anna Rosati
   • Salvatore De Masi
   • Renzo Guerrini

   Systematic Review 19 September 2018 Pages: 997 - 1009

   

3. Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis

   • Andrew T. Olagunju
   • Scott R. Clark
   • Bernhard T. Baune

   Systematic Review 28 August 2018 Pages: 1011 - 1023

   

4. From LBR-101 to Fremanezumab for Migraine

   • Marcelo E. Bigal
   • Alan M. Rapoport
   • Ernesto Aycardi

   Review Article 11 October 2018 Pages: 1025 - 1037

   

5. Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis

   • Stefanie Kuerten
   • Leila J. Jackson
   • Timothy L. Vollmer

   Review Article Open access 12 October 2018 Pages: 1039 - 1051

   

6. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

   • Lesley Taylor
   • Barry Gidal
   • Gilmour Morrison

   Original Research Article Open access 30 October 2018 Pages: 1053 - 1067

   

7. Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis

   • Dimitrios Papadopoulos
   • Dimos-Dimitrios D. Mitsikostas

   Original Research Article 01 August 2018 Pages: 1069 - 1078